Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

(2017) Christian Marth et al.   EUROPEAN JOURNAL OF CANCER

Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2 -Mutated Cancer or PARP-Sensitive Tumor Types

(2017) Jing Niu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

(2016) Nadia Harbeck et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

(2016) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study

(2016) Lisa M. Landrum et al.   GYNECOLOGIC ONCOLOGY

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

(2015) Robert L. Coleman et al.   GYNECOLOGIC ONCOLOGY

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

(2014) C. H. Smorenburg et al.   ANNALS OF ONCOLOGY

Squamous Cell Carcinomas of the Tongue and Oral Cavity as Secondary Malignancies: What Factors Are Implicated?

(2013) F. Muggia   ONCOLOGIST

Squamous Cell Carcinoma of the Oral Cavity in Nonsmoking Women: A New and Unusual Complication of Chemotherapy for Recurrent Ovarian Cancer?

(2012) T. L. Cannon et al.   ONCOLOGIST

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

(2011) Ninh M. La-Beck et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

(2011) S. Kummar et al.   CANCER RESEARCH

Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy

(2011) Alberto Gabizon et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer

(2011) Stan B. Kaye et al.   JOURNAL OF CLINICAL ONCOLOGY

Delayed Neoplastic and Renal Complications in Women Receiving Long-term Chemotherapy for Recurrent Ovarian Cancer

(2010) F. Muggia et al.   JNCI-Journal of the National Cancer Institute

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Liquid chromatography–mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase

(2008) Robert A. Parise et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES